In this type the enzyme glucose-6-phosphatase is defective in the liver, kidney, and small intestine, where it normally functions. However, the metabolic problem is centered in the liver.
Hidradenitis suppurativa or HS is a poorly studied skin disease that affects areas bearing apocrine sweat glands and hair follicles; such as the underarms, groin and buttocks, and under the breasts in women.
Hidradenitis suppurativa is a deep-seated inflammatory condition that produces lesions which mainly occur in the axillae and groins. Hidradenitis is primarily an acne-like follicular occlusion disease where apocrine glands only become involved in the context of peri-follicular inflammation – it is not a primary disease of apocrine glands.
Hidradenitis suppurativa is primarily a disease of occlusion (obstruction) and inflammation of the apocrine (odor) sweat glands of the groin and axilla (armpit). It is similar to acne, which is a disease of the sebaceous (oil) glands in the skin. Hidradenitis develops when ducts from the apocrine glands to the skin surface become blocked, leading to a red swollen area on the skin and to the formation of cysts, infection and scarring.
Blocked sinuses, which rarely occur in kids under age five, are often caused by a cold or hay fever, according to St. Louis Children’s Hospital.
New research shows that bacteria lurking in household dust produce chemicals that may trigger asthma and asthma-related symptoms such as wheezing. These bacterial chemicals, called endotoxins, particularly those found on bedroom floors, were linked with increased respiratory problems in adults. This study, supported by the National Institute of Environmental Health Sciences (NIEHS), a part of the National Institutes of Health, is the first nationwide study of endotoxins in the household environment, and it involved analysis of more than 2,500 dust samples from 831 homes across the U.S.
Taking advantage of a technique called polymerase chain reaction (PCR), scientists have developed a molecular-based method for checking food safety.
A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today. The novel antibiotic, PA-824, may shorten the time needed to treat tuberculosis (TB), a contagious disease that claims approximately two million lives worldwide each year. In partnership with the non-profit New York-based Global Alliance for TB Drug Development (TB Alliance), NIAID contributed to the drug candidate?s preclinical safety and efficacy testing in animal models. Now, a clinical trial to assess PA-824?s safety, sponsored by the TB Alliance, has opened at a medical clinic in Lincoln, NE.
New research on a bacterium that can survive encounters with specific immune system cells has strengthened scientists? belief that these plentiful white blood cells, known as neutrophils, dictate whether our immune system will permit or prevent bacterial infections. A paper describing the research was released today online in The Journal of Immunology. Frank R. DeLeo, Ph.D., of Rocky Mountain Laboratories (RML), part of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, directed the work at RML, in Hamilton, MT, in collaboration with lead author Dori L. Borjesson, D.V.M., Ph.D., of the University of Minnesota in St. Paul.
Researchers at Mount Sinai School of Medicine in New York report they have found a key to controlling the HIV infection.